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We read with great interest the recent report by Gonano et al.
[1] describing the effects of antithrombin versus placebo in
the coagulation profile of a group of patients with severe
sepsis. However, we thought that several important issues
needed to be addressed in regards to hypercoagulability and
thrombelastography (TEG). First, hypercoagulability was not
clearly defined in the study. Second, neither Coagulation Index
(CI) nor Thrombodynamic Potential Index (an alternative TEG
index of hypercoagulability) [2] were calculated or reported.
Third, conventional studies of hypercoagulability were not
performed in parallel. Fourth, Table 2 in the paper shows that
some patients had low fibrinogen, platelets, and prolonged
activated partial thromboplastin time with a probably
‘hypocoagulable’ thrombelastogram (CI lower than -3) profile.
Contrary to the authors’ statements, there are previously
described studies of hypercoagulability in sepsis using TEG.
A decade ago, Grant and Hadley [3] described the coagula-
tion changes of 27 neonates with sepsis and found a ‘hypo-
coagulability’ profile in 85% of the neonates studied. These
findings are also supported in animal data for which our lab
has shown similar hypocoagulable patterns in a porcine
model of sepsis using TEG [4].
Hypercoagulability is defined in thromboelastography as a CI
greater than +3 [2]. This means that patients with reaction
time (r), coagulation time (k), alpha angle, or maximum
amplitude on the ‘hypercoagulable side’ may still fall within a
normal CI range and not meet criteria to be called
‘hypercoagulable’. We believe that it would have been of
great interest if the authors had provided the actual CI values,
as well as the percentage of patients with hypercoagulable
and hypocoagulable profiles.
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CI = Coagulation Index; TEG = thrombelastography.
Authors’ response
Stephan C Kettner and Christopher Gonano
We appreciate the interest of Dr Puana and Dr Nates in our
article and their comments. Standard TEG parameters have
been described as they are most commonly used by clinicians.
Calculated indexes, however, add limited information. No
patient with severely altered coagulation was included in our
study, due to the complex inclusion and exclusion criteria of the
KyberSept trial. We actually excluded patients with severe
coagulation abnormalities, who might have benefited most from
antithrombin therapy. A recent analysis of the KyberSept trial
showed that high-dose antithrombin in septic patients with
disseminated intravascular coagulation resulted in decreased
mortality rates [5]. We agree that hypercoagulation may not be
present in septic patients with disseminated intravascular
coagulation, as hyperfibrinolysis may cause straight line TEG.
We knowingly did not cite the study by Grant and Hadley [3],
for several reasons. First, the coagulation system in neonates
is profoundly different compared to adults [6], and normal
values for TEG have not been established in neonates [7].
Second, causes and incidence of sepsis in neonates are
completely different compared to adults [8]. Third, the
immune system in neonates is immature [9]. Fourth, we feel
Grant’s interpretation that TEG has a 96% sensitivity of and a
96% specificity for sepsis is inappropriate, as if every
abnormal TEG in neonates should be associated with sepsis.
Of course there are other causes for abnormal TEGs in
neonates.Page 2 of 2
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